This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
StatPearls [Internet].
Show detailsIntroduction
The hemoglobin A1c test, also known as glycated hemoglobin, glycosylated hemoglobin, HbA1c, or simply A1c, is used to measure a person's level of glucose control. The test shows average blood sugar levels over the past 90 days, expressed as a percentage. The test can also be used to diagnose diabetes mellitus.[1]
Hemoglobin is a protein found exclusively in red blood cells, giving blood its bright red color. Since red blood cells have an average lifespan of about three months, the A1c test measures the hemoglobin levels in the bloodstream at the time of testing, which is why the A1c test serves as an indicator of blood sugar control.
The primary role of hemoglobin is to carry oxygen from the lungs to all the cells in the body. Hemoglobin becomes glycated or coated with glucose from the bloodstream. As blood glucose levels rise, more glucose attaches to the hemoglobin protein. Higher blood glucose levels result in more glycated hemoglobin, leading to a higher A1c level.[2]
Etiology and Epidemiology
The Diabetes Control and Complications Trial (DCCT) [3] was a landmark study that provided extensive data on A1c and its correlation to blood glucose levels, establishing specific treatments to target A1c goals. Following the completion of the trial, the National Glycohemoglobin Standardization Program (NGSP) was formed to define a standardized assay for A1c measurement across laboratories.
The DCCT trial reported that a higher mean A1c level was the dominant predictor of diabetic retinopathy progression. Tighter glucose control, indicated by HbA1c levels in the 7% range or lower, was correlated with a 35 to 76% decrease in microvascular complications, such as retinopathy, nephropathy, and neuropathy, in patients with type 1 diabetes. In addition to predicting the progression of microvascular complications through A1c levels, the DCCT extension into the EDIC study showed long-term benefits in cardiovascular risk and mortality for patients with lower HbA1c levels.[4][5][6]
Pathophysiology
People with diabetes mellitus need regular A1c testing to ensure their average blood glucose levels are within the target range. The American Diabetes Association (ADA) recommends checking HbA1c twice a year for patients who are stable and well-controlled and every 3 months for those with medication changes or who are not well-controlled.
Specimen Requirements and Procedure
The HbA1c test can be performed as a point of care (POC), a STAT test, or by sending a sample to a laboratory. The POC test uses a STAT analyzer to measure A1c from a capillary fingerstick. The laboratory test uses a teaspoon of blood drawn from a venous sample into a K2 EDTA (lavender top) tube. The sample gets processed as whole blood.
Diagnostic Tests
The venous sample A1c test may be used as a diagnostic tool in clinical practice when determining diabetes risk or onset. Due to the variability of capillary POC testing, any A1c test conducted using a capillary sample should be confirmed with a venous sample before rendering a diagnosis.
An HbA1c value below 5.7% is considered normal or in the non-diabetic range. A value between 5.7% and 6.4% indicates prediabetes mellitus, whereas a 6.5% or higher level is diagnostic for diabetes mellitus.
Tests should be sent to a laboratory certified by the NGSP to ensure results are standardized.[7][8]
Testing Procedures
The HbA1c test performed using a POC machine in a clinic may be less accurate than one drawn from a venous sample and processed in a laboratory. Results can differ by as much as 0.5% between different laboratories.
The HbA1c test should be performed using an NGSP-approved method.
Interfering Factors
There are several conditions where the HbA1c test can produce inaccurate results. Individuals with sickle cell anemia, thalassemia, anemia, kidney failure, liver disease, or those receiving blood transfusions can experience altered results due to the longevity of the red blood cell. HbA1c measurement in these patients must be interpreted cautiously and confirmed with plasma glucose samples to diagnose diabetes mellitus.[9]
A falsely low HbA1c value can result from several conditions, including high altitude, pregnancy, hemorrhage, blood transfusion, erythropoietin administration, iron supplementation,[10] hemolytic anemia, chronic kidney failure, liver cirrhosis, alcoholism, sickle cell anemia,[11] and spherocytosis. Vitamin C supplementation can increase or decrease HbA1c levels depending on the method used.
Conversely, a falsely high HbA1c value can be due to insufficient iron in the blood. This condition can result from iron deficiency anemia,[12] infection-induced anemia, or tumor-induced anemia. In addition, hemoglobinopathies such as thalassemia and B12 deficiency [10][13] can cause a falsely high HbA1c value. Other causes of falsely high HbA1c levels include hypertriglyceridemia, organ transplantation, and hyperglycation in certain ethnic groups. Medications such as immunosuppressants and protease inhibitors can sometimes lead to a falsely high HbA1c value.[9][7][14][15]
Results, Reporting, and Critical Findings
Relationship Between A1c and Glucose Levels
The HbA1c percentage reflects the average glucose level in a patient's body over the past 90 days.[16][17][18]
Clinical Significance
Hemoglobin A1c serves as an indicator of overall glycemic control and a reflection of the average blood sugar over the past 3 months.[2]
Quality Control and Lab Safety
Laboratories use several methods to determine HbA1c, with high-performance liquid chromatography being one of the most popular methods due to its ability to eliminate labile components used by other methods, such as immunoassay or affinity chromatography.[19]
POC devices are widely used to measure HbA1c levels. However, the range of POC machines available can make selecting the most suitable one for a particular practice challenging. There is limited information comparing the different machines. When using POC testing, it is important to note that POC values are typically lower than those reported by laboratory tests, with the average difference being −0.5%.
Enhancing Healthcare Team Outcomes
All clinicians caring for diabetic patients need a clear understanding of HbA1c and its significance. In general, HbA1c reflects the average glucose concentration over 3 months.
Hemoglobin A1c is often used as an outcome measure to determine whether an intervention in a population is successful by showing a decrease in HbA1c by a certain percentage. There is a movement within the medical community to shift away from using HbA1c as an exclusive standard of care test to measure patient response to treatment. The newest proposed methods are the estimated average glucose and the glucose time in the range.[20] These methods use data obtained from continuous glucose monitors that record blood glucose levels around the clock. These methods can also give healthcare professionals a more accurate view of the blood sugar average and fluctuations, but these methods are not available to all patients on a widespread basis.
According to ADA guidelines, HA1c levels should be measured twice a year in stable patients and at least four times in patients with glucose fluctuations or those who have changed their diabetic treatment. Hemoglobin A1c is one of the preferred diabetes diagnostic tests today. The blood draw can occur anytime, and no special handling requirements exist. However, to ensure that the A1c value is correct, clinicians must be aware of the causes of false-positive and false-negative results.
Given that many diabetic patients are treated in outpatient settings, it is essential for diabetes care nurses to understand HbA1c results and know when to refer patients to an endocrinologist for further evaluation. Pharmacists must also fully understand and interpret this test, as they are involved in glycemic management medication, agent selection, dosing, and monitoring. The nurse and pharmacist must inform the treating clinician regarding any changes in hemoglobin A1c and verify patient medication compliance. Hemoglobin A1c is a valuable tool in managing diabetes mellitus and other glycemic control disorders, but to be effective, it functions best in an interprofessional healthcare team environment.
References
- 1.
- Gilstrap LG, Chernew ME, Nguyen CA, Alam S, Bai B, McWilliams JM, Landon BE, Landrum MB. Association Between Clinical Practice Group Adherence to Quality Measures and Adverse Outcomes Among Adult Patients With Diabetes. JAMA Netw Open. 2019 Aug 02;2(8):e199139. [PMC free article: PMC6694385] [PubMed: 31411713]
- 2.
- Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104. [PMC free article: PMC4933534] [PubMed: 27398023]
- 3.
- Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. [PubMed: 8366922]
- 4.
- Nathan DM., DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. [PMC free article: PMC3867999] [PubMed: 24356592]
- 5.
- Nathan DM. Realising the long-term promise of insulin therapy: the DCCT/EDIC study. Diabetologia. 2021 May;64(5):1049-1058. [PubMed: 33550441]
- 6.
- Lachin JM, Orchard TJ, Nathan DM., DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):39-43. [PMC free article: PMC3868002] [PubMed: 24356596]
- 7.
- American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70. [PubMed: 30559232]
- 8.
- Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569-576. [PubMed: 29507945]
- 9.
- Heinemann L, Freckmann G. Quality of HbA1c Measurement in the Practice: The German Perspective. J Diabetes Sci Technol. 2015 May;9(3):687-95. [PMC free article: PMC4604529] [PubMed: 25691655]
- 10.
- Pilla R, Palleti SK, Rayana R, Skss SR, Abdul Razzack A, Kalla S. Glycated Haemoglobin (HbA1c) Variations in Nondiabetics With Nutritional Anemia. Cureus. 2020 Nov 13;12(11):e11479. [PMC free article: PMC7735166] [PubMed: 33329975]
- 11.
- Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, Wilson JG, Sacks DB, Jacobs DR, Carson AP, Luo X, Gjelsvik A, Reiner AP, Naik RP, Liu S, Musani SK, Eaton CB, Wu WC. Association of Sickle Cell Trait With Hemoglobin A1c in African Americans. JAMA. 2017 Feb 07;317(5):507-515. [PMC free article: PMC5713881] [PubMed: 28170479]
- 12.
- Guo W, Zhou Q, Jia Y, Xu J. Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review. Med Sci Monit. 2019 Nov 07;25:8371-8378. [PMC free article: PMC6857442] [PubMed: 31696865]
- 13.
- Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L. Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency. J Intern Med. 1990 Feb;227(2):133-6. [PubMed: 2299304]
- 14.
- Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014 Feb;29(2):388-94. [PMC free article: PMC3912281] [PubMed: 24002631]
- 15.
- Shepard JG, Airee A, Dake AW, McFarland MS, Vora A. Limitations of A1c Interpretation. South Med J. 2015 Dec;108(12):724-9. [PubMed: 26630892]
- 16.
- van 't Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care. 2010 Jan;33(1):61-6. [PMC free article: PMC2797987] [PubMed: 19808928]
- 17.
- Sayed A, Alyafei F, De Sanctis V, Soliman A, Elgamal M. Translating the HbA1c assay into estimated average glucose values in children and adolescents with type 1 diabetes mellitus. Acta Biomed. 2018 May 23;89(S5):22-26. [PMC free article: PMC6179094] [PubMed: 30049928]
- 18.
- Lai LC. Global standardisation of HbA1c. Malays J Pathol. 2008 Dec;30(2):67-71. [PubMed: 19291914]
- 19.
- Kawano K. Quality control, quality assessment of laboratory tests, HbA1c. Southeast Asian J Trop Med Public Health. 1999;30 Suppl 3:117-21. [PubMed: 10926271]
- 20.
- Saboo B, Kesavadev J, Shankar A, Krishna MB, Sheth S, Patel V, Krishnan G. Time-in-range as a target in type 2 diabetes: An urgent need. Heliyon. 2021 Jan;7(1):e05967. [PMC free article: PMC7814148] [PubMed: 33506132]
Disclosure: Emily Eyth declares no relevant financial relationships with ineligible companies.
Disclosure: Roopa Naik declares no relevant financial relationships with ineligible companies.
- [Analytical problems in determination of hemoglobin A1c and the different ways of its interpretation].[Orv Hetil. 2009][Analytical problems in determination of hemoglobin A1c and the different ways of its interpretation].Góth L. Orv Hetil. 2009 Apr 19; 150(16):747-51.
- Review Glycated hemoglobin A1c as a modern biochemical marker of glucose regulation.[Med Pregl. 2014]Review Glycated hemoglobin A1c as a modern biochemical marker of glucose regulation.Kojić Damjanov S, Đerić M, Eremić Kojić N. Med Pregl. 2014 Sep-Oct; 67(9-10):339-44.
- Average glucose from hemoglobin A(1c) for altered red blood cell lifetimes: Predictions based on a model for hemoglobin A1c formation.[Clin Chim Acta. 2017]Average glucose from hemoglobin A(1c) for altered red blood cell lifetimes: Predictions based on a model for hemoglobin A1c formation.Molinaro R, Herman JH, Stickle DF. Clin Chim Acta. 2017 Nov; 474:124-129. Epub 2017 Sep 18.
- Elevated Hemoglobin A1C Levels Correlate with Blood Glucose Elevation in Diabetic Patients following Local Corticosteroid Injection in the Hand: A Prospective Study.[Plast Reconstr Surg. 2015]Elevated Hemoglobin A1C Levels Correlate with Blood Glucose Elevation in Diabetic Patients following Local Corticosteroid Injection in the Hand: A Prospective Study.Kim N, Schroeder J, Hoffler CE, Matzon JL, Lutsky KF, Beredjiklian PK. Plast Reconstr Surg. 2015 Oct; 136(4):474e-479e.
- Review Hemoglobin A1c and Permissive Hyperglycemia in Patients in the Intensive Care Unit with Diabetes.[Crit Care Clin. 2019]Review Hemoglobin A1c and Permissive Hyperglycemia in Patients in the Intensive Care Unit with Diabetes.Balintescu A, Mårtensson J. Crit Care Clin. 2019 Apr; 35(2):289-300. Epub 2019 Jan 24.
- Hemoglobin A1C - StatPearlsHemoglobin A1C - StatPearls
Your browsing activity is empty.
Activity recording is turned off.
See more...